tiprankstipranks
Trending News
More News >

Palvella Therapeutics Holds Annual Stockholders Meeting

Story Highlights
Palvella Therapeutics Holds Annual Stockholders Meeting

Don’t Miss TipRanks’ Half-Year Sale

Palvella Therapeutics ( (PVLA) ) just unveiled an announcement.

On June 10, 2025, Palvella Therapeutics held its Annual Meeting of Stockholders virtually, where key decisions were made regarding the company’s governance and financial oversight. Elaine J. Heron, Ph.D., and Tadd S. Wessel were elected as Class II directors, and Ernst & Young LLP’s appointment as the independent registered public accounting firm for 2025 was ratified. Additionally, the stockholders approved the compensation of the company’s named executive officers for 2024, indicating continued support for the company’s leadership and strategic direction.

The most recent analyst rating on (PVLA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for rare and serious diseases. The company is committed to advancing its pipeline of therapeutic candidates to address unmet medical needs.

Average Trading Volume: 81,498

Technical Sentiment Signal: Hold

Current Market Cap: $290M

Find detailed analytics on PVLA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1